Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

Oncogene volume 20, pages 6718–6723 (2001)Cite this article

Abstract

Androgen deprivation therapy for advanced prostate cancer is often effective, but not curative. Molecular pathways mediating the therapeutic response and those contributing to the subsequent hormone-refractory cell growth remain poorly understood. Here, cDNA microarray analysis of human CWR22 prostate cancer xenografts during the course of androgen deprivation therapy revealed distinct global gene expression profiles in primary, regressing and recurrent tumors. Elucidation of the genes involved in the transition between these states implicated specific molecular mechanisms in therapy failure and tumor progression. First, we identified a set of androgen-responsive genes whose expression decreased during the therapy response, but was then systematically restored in the recurrent tumors. In addition, altered expression of genes that encode known targets of rapamycin or that converge on the PI3K/AKT/FRAP pathway was observed in the recurrent tumors. Further suggestion for the involvement of these genes in hormone-refractory prostate cancer came from the observation that cells established from the recurrent xenografts were strongly inhibited in vitro by rapamycin. The results of this functional genomic analysis suggest that the combined effect of re-expression of androgen-responsive genes as well as the activation of rapamycin-sensitive signaling may drive prostate cancer progression, and contribute to the failure of androgen-deprivation therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL . 1999 Mol. Cell Biol. 19: 5143–5154

  • Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM . 2000 Cancer Res. 60: 6134–6141

  • Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT . 1996 EMBO J. 15: 5256–5267

  • Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP . 1999 J. Natl. Cancer Inst. 91: 1758–1764

  • Cheng L, Sun J, Pretlow TG, Culp J, Yang NS . 1996 J. Natl. Cancer Inst. 88: 607–611

  • Craft N, Sawyers CL . 1998 Cancer Metastasis Rev. 17: 421–427

  • Craft N, Shostak Y, Carey M, Sawyers CL . 1999 Nat. Med. 5: 280–285

  • Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H . 1994 Cancer Res. 54: 5474–5478

  • Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ . 1994 Cancer Res. 54: 903–907

  • Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS . 1998 Cancer Res. 58: 5718–5724

  • Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A, Abraham RT, Lawrence Jr JC, Houghton PJ . 1998 Mol. Pharmacol. 54: 815–824

  • Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS . 1998 Cancer Res. 58: 5009–5013

  • Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN . 1993 Cell 73: 585–596

  • Liu J, Farmer Jr JD, Lane WS, Friedman J, Weissman I, Schreiber SL . 1991 Cell 66: 807–815

  • Mousses S, Bittner ML, Chen Y, Doughtery ER, Baxevanis A, Meltzer PS, Trent JM . 2000 Functional Genomics: Gene Expression Analysis by cDNA Microarrays Livesey FJ and Hunt SP (eds) Oxford University Press: Oxford pp 113–137

    Google Scholar 

  • Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG . 1996 Cancer Res. 56: 3042–3046

  • Nair SC, Rimerman RA, Toran EJ, Chen S, Prapapanich V, Butts RN, Smith DF . 1997 Mol. Cell.Biol. 17: 594–603

  • Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC . 1999 Oncogene 18: 6322–6329

  • Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, et al. 1993 J. Natl. Cancer Inst. 85: 394–398

  • Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT . 1995 J. Biol. Chem. 270: 815–822

  • Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT . 2000 Cancer Res. 60: 3504–3513

  • Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Pretlow TG . 1994 Cancer Res. 54: 6049–6052

Download references

Acknowledgements

Supported in part by NIH grant CA57179 (to T Pretlow), CaPCURE (L Bubendorf) and Swiss National Science Foundation (L Bubendorf and U Wagner) and the Krebsliga beider Basel and Novartis Foundation (U Wagner).

Author information

Authors and Affiliations

  1. Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, Maryland, USA

    Spyro Mousses, Urs Wagner, Yidong Chen, Lukas Bubendorf, Michael Bittner, Abdel G Elkahloun & Olli-P Kallioniemi

  2. Institute of Pathology, University of Basel, Basel, Switzerland

    Urs Wagner & Lukas Bubendorf

  3. Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20850, Maryland, USA

    J W Kim & Jane B Trepel

  4. Institute of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

    Thomas Pretlow

Authors
  1. Spyro Mousses
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Urs Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yidong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lukas Bubendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael Bittner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Pretlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abdel G Elkahloun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jane B Trepel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Olli-P Kallioniemi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olli-P Kallioniemi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mousses, S., Wagner, U., Chen, Y. et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20, 6718–6723 (2001). https://doi.org/10.1038/sj.onc.1204889

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204889

Keywords

This article is cited by

Search

Advanced search

Quick links